ストックスクリーナーアプリを入手
41.69
2.33%
0.95
プレマーケット:
41.20
-0.49
-1.18%
前日終値:
$40.74
開ける：
$41.06
24時間の取引高:
4.21M
Relative Volume:
1.56
時価総額：
$10.83B
収益：
$2.29B
当期純損益:
$677.90M
株価収益率:
17.55
EPS:
2.3753
ネットキャッシュフロー:
$779.77M
1週間 パフォーマンス:
-6.84%
1か月 パフォーマンス:
-2.25%
6か月 パフォーマンス:
+11.53%
1年 パフォーマンス:
+8.88%
1日の値動き範囲:
$40.69
$41.83
1週間の範囲:
$39.71
$45.01
52週間の値動き範囲:
$32.38
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
41.69 | 10.58B | 2.29B | 677.90M | 779.77M | 2.3753 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2025-11-18 | 開始されました | Wolfe Research | Peer Perform |
| 2025-11-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | 再開されました | Barclays | Equal Weight |
| 2025-09-17 | 再開されました | Barclays | Equal Weight |
| 2025-09-17 | 開始されました | Goldman | Buy |
| 2025-07-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-16 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2024-09-19 | 開始されました | UBS | Neutral |
| 2024-04-11 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 開始されました | BTIG Research | Buy |
| 2023-12-15 | 開始されました | Citigroup | Buy |
| 2023-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2023-08-22 | 繰り返されました | Oppenheimer | Outperform |
| 2023-08-08 | 開始されました | SVB Securities | Market Perform |
| 2023-07-11 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 再開されました | Piper Sandler | Overweight |
| 2023-03-09 | 開始されました | Wells Fargo | Overweight |
| 2023-01-26 | 開始されました | Credit Suisse | Outperform |
| 2022-10-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-11-03 | 再開されました | Jefferies | Buy |
| 2021-10-07 | 開始されました | Jefferies | Buy |
| 2021-08-06 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-15 | 開始されました | H.C. Wainwright | Buy |
| 2021-05-18 | 再開されました | Goldman | Sell |
| 2021-03-31 | 開始されました | Credit Suisse | Outperform |
| 2021-03-12 | 開始されました | Wolfe Research | Outperform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-03-18 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 開始されました | Goldman | Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Underweight |
| 2018-05-11 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | Needham | Buy |
| 2017-10-17 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2017-10-16 | 繰り返されました | SunTrust | Buy |
| 2017-09-22 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
| 2017-09-12 | 繰り返されました | Needham | Buy |
| 2017-07-14 | 開始されました | SunTrust | Buy |
| 2017-03-31 | 開始されました | Needham | Buy |
| 2017-03-16 | 開始されました | Oppenheimer | Perform |
| 2017-02-28 | ダウングレード | Stifel | Buy → Hold |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2016-10-10 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 繰り返されました | Stifel | Buy |
すべてを表示
Exelixis Inc (EXEL) 最新ニュース
A Look At Exelixis (EXEL) Valuation As Analyst Optimism Builds Around Its Oncology Pipeline - simplywall.st
EXEL: Zanzalintinib advances toward launch as pivotal trials and franchise expansion drive future growth - TradingView
Forecasting The Future: 11 Analyst Projections For Exelixis - Sahm
Is Improving Analyst Sentiment Reframing Exelixis (EXEL) Oncology Pipeline As A Core Valuation Anchor? - simplywall.st
Exelixis (EXEL) EVP Haley granted 40,459 RSUs vesting from 2027 - Stock Titan
Exelixis (NASDAQ: EXEL) CEO granted RSUs, gifts 100K shares - Stock Titan
Exelixis stock falls after rival Merck trial shows better results - Investing.com
RBC Capital Lowers Exelixis (EXEL) Price Target to $43 | EXEL St - GuruFocus
Royal Bank Of Canada Issues Pessimistic Forecast for Exelixis (NASDAQ:EXEL) Stock Price - MarketBeat
Why Exelixis (EXEL) Stands Out as a Leading Value Investment for Long-Term Growth - Bitget
Exelixis (NASDAQ:EXEL) Shares Down 9.4% After Analyst Downgrade - MarketBeat
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating - marketscreener.com
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Growth With A 7.05% Potential Upside - DirectorsTalk Interviews
Exelixis (NASDAQ:EXEL) Downgraded by Wall Street Zen to Buy - MarketBeat
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion - Investing.com Nigeria
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade - Nasdaq
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade - The Motley Fool
Citigroup Inc. Sells 365,552 Shares of Exelixis, Inc. $EXEL - MarketBeat
EXEL PE Ratio & Valuation, Is EXEL Overvalued - Intellectia AI
EXEL Should I Buy - Intellectia AI
Exelixis Director Julie Smith Sells Over 106K Shares - TradingView
Exelixis (NASDAQ:EXEL) EVP Dana Aftab Sells 47,918 Shares - MarketBeat
Exelixis (NASDAQ: EXEL) EVP sells 47,918 shares in open trade - Stock Titan
Exelixis EVP Sells Shares Worth Over $2 Million - TradingView
Intech Investment Management LLC Grows Stake in Exelixis, Inc. $EXEL - MarketBeat
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case - ChartMill
Is It Too Late To Consider Exelixis (EXEL) After Its Surging Share Price? - Yahoo Finance
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March 2026 - BioSpace
Exelixis Cancer Pipeline Progress Puts Focus On Valuation And Growth Potential - Yahoo Finance
EXEL (NASDAQ: EXEL) insider Dana T Aftab sells 29,873 shares for $1.32M - Stock Titan
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March - Business Wire
Oncology Market Set to Nearly Triple: Here Are Five Companies Le - GuruFocus
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge - PR Newswire
Responsive Playbooks and the EXEL Inflection - Stock Traders Daily
Here's Why Exelixis (EXEL) is a Strong Momentum Stock - Yahoo Finance
Exelixis reports solid earnings – are new highs back on the table? - MSN
Exelixis (NASDAQ:EXEL) EVP Dana Aftab Sells 29,873 Shares - MarketBeat
Exelixis (EXEL) R&D EVP sells 29,873 shares at $44.35 - Stock Titan
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Leader With 8.11% Potential Upside - DirectorsTalk Interviews
Exelixis (EXEL) Q4 2025 Earnings Call Transcript - AOL.com
Vanguard Group Inc. Lowers Position in Exelixis, Inc. $EXEL - MarketBeat
Advisors Preferred LLC Purchases 33,344 Shares of Exelixis, Inc. $EXEL - MarketBeat
Exelixis (NASDAQ:EXEL) Upgraded at Wall Street Zen - MarketBeat
Will Exelixis Inc. outperform its industry peersTrade Exit Report & AI Optimized Trading Strategy Guides - mfd.ru
Exelixis (NASDAQ:EXEL) Director Jack Wyszomierski Sells 99,574 Shares - MarketBeat
Exelixis director Wyszomierski sells $4.38 million in stock By Investing.com - Investing.com UK
Exelixis director Wyszomierski sells $4.38 million in stock - Investing.com
Exelixis (EXEL) director sells 99,574 shares after option exercise - Stock Titan
Published on: 2026-02-21 01:41:50 - mfd.ru
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026 - Nasdaq
Exelixis Inc (EXEL) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):